SCHEMBL3550072

SCHEMBL3550072

O=[N+]([O-])c1ccc(Cl)c(C(F)(F)F)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.47
▸ AR P10275 1/20 0.46
▸ GPR35 Q9HC97 3/20 0.46
▸ TSHR P16473 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ TXNRD1 Q16881 1/20 0.43
▸ TXNRD3 Q86VQ6 1/20 0.43
▸ TXNRD2 Q9NNW7 1/20 0.43
▸ MAPK1 P28482 1/20 0.42
▸ VCAM1 P19320 1/20 0.41
▸ CRHBP P24387 1/20 0.39
▸ CRHR2 Q13324 1/20 0.39
▸ TTR P02766 2/20 0.38
▸ P2RX1 P51575 1/20 0.38
▸ NOTUM Q6P988 1/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3294774 0.81 TDP1 (0.48) TDP1ARTSHRALDH1A1CYP3A4
SCHEMBL29449833 0.81 TDP1 (0.48) TDP1ARTSHRALDH1A1CYP3A4
SCHEMBL9871485 0.79 TDP1 (0.47) TDP1ARTSHRALDH1A1CYP3A4
SCHEMBL3309493 0.79 TDP1 (0.47) TDP1ARTSHRALDH1A1CYP3A4
SCHEMBL4509153 0.77 TDP1 (0.48) TDP1ARTSHRALDH1A1CYP3A4
SCHEMBL11079893 0.77 TDP1 (0.52) TDP1GPR35TSHRALDH1A1CYP3A4
SCHEMBL1026141 0.76 GPR35 (0.41) TDP1ARGPR35TSHRALDH1A1
SCHEMBL31170798 0.76 TDP1 (0.67) TDP1GPR35TSHRALDH1A1CYP3A4
SCHEMBL5595026 0.76 TDP1 (0.67) TDP1GPR35TSHRALDH1A1CYP3A4
SCHEMBL3550579 0.76 TDP1 (0.47) TDP1ARTSHRALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652041-B2 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
EP-1856053-A1 CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-11-21 — — EP disclosed
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-20 — — US disclosed
WO-2006076706-A1 CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MAP3K21, HIPK4, MAP3K20 TDP1 2815/4885AR 2056/4885GPR35 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback